Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2018
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Amphastar Pharmaceuticals (AMPH) PT Raised to $25 at Needham & Company
November 9, 2018 9:14 AM ESTNeedham & Company analyst Serge Belanger raised the price target on Amphastar Pharmaceuticals (NASDAQ: AMPH) to $25.00 (from $20.00) while maintaining a Buy rating.
Belanger commented, "AMPH delivered 3Q18 results that beat both top- and bottom-line Street consensus estimates, benefiting from a surprisising significant uptick in... More
Amphastar Pharma (AMPH) Tops Q3 EPS by 1c
November 8, 2018 4:24 PM ESTAmphastar Pharma (NASDAQ: AMPH) reported Q3 EPS of $0.12, $0.01 better than the analyst estimate of $0.11. Revenue for the quarter came in at $75.5 million versus the consensus estimate of $74.73 million.
For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.
... More